-

STUB Stockholders with Large Losses Should Contact Robbins LLP to Learn How to Lead the StubHub Holdings, Inc. Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP:

Robbins LLP is investigating allegations that the registration statement issued in support of StubHub's IPO was materially false and misleading.

Share

Company: StubHub Holdings, Inc. (NYSE: STUB) operates a global ticketing marketplace for live events where fans can buy tickets from sellers of all types through the Company’s StubHub and viagogo websites and mobile applications.

What is the class period? The class includes shareholders who purchased StubHub Holdings, Inc. common stock pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's September 2025 initial public offering ("IPO").

What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired StubHub Holdings, Inc. pursuant to the Company's allegedly false statements in support of its IPO.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

What are the allegations? According to the complaint, the registration statement issued in support of StubHub's IPO was materially false and misleading and omitted to state: (1) the Company was experiencing changes in the timing of payments to vendors; (2) those changes had a significant adverse impact on free cash flow, including trailing 12 months (“TTM”) free cash flow; and (3) as a result, the Company’s free cash flow reports were materially misleading.

On November 13, 2025, StubHub issued a press release announcing disappointing financial results for the third quarter 2025, which ended September 30, 2025. The press release revealed free cash flow of negative $4.6 million in the quarter, a 143% decrease from the Company’s free cash flow in the year ago period, which was positive $10.6 million. The press release further revealed the Company’s net cash provided by operating activities was only $3.8 million, a 69.3% decrease from the year ago period, where the Company reported $12.4 million in net cash provided by operating activities.

The same day, the Company filed its Form 10-Q for the same quarterly period ended September 30, 2025, with the SEC. The quarterly report revealed that this year-over-year decrease “primarily reflects changes in the timing of payments to vendors.”

On this news, StubHub’s stock price fell $3.95 per share, or 20.9%, to close at $14.87 per share on November 14, 2025. By the commencement of the class action, the Company’s stock was trading as low as $10.31 per share, a nearly 56% decline from the $23.50 per share IPO price.

What can you do now? You may be eligible to participate in the class action against StubHub Holdings, Inc. Shareholders who wish to serve as lead plaintiff for the class must file their papers with the court by January 23, 2026. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against StubHub Holdings, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:STUB

Release Versions
$Cashtags

Contacts

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Robbins LLP Urges GOSS Stockholders to Contact the Firm for Information About the Class Action Against Gossamer Bio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.For more information, submit a form, email att...

Robbins LLP Urges IBRX Stockholders to Contact the Firm for Information About the Class Action Against ImmunityBio, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between January 19, 2026 and March 25, 2026. ImmunityBio is a biotechnology company and ANKTIVA is the Company's lead biologic product. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? January 19, 2026 – March 25, 202...

Robbins LLP Reminds ALDX Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Case Against Aldeyra Therapeutics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, 2023 and March 16, 2026. Defendant Aldeyra describes itself as a “biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases.” Pertinent to this action is reproxalap, which is a novel reactive aldehyde species (RASP) inhib...
Back to Newsroom